An analysis of risk factors for early complications after liver transplantation

Jie EnBo; Xuan FengHui; Sun XiaoDong; Sun DaWei; Lu: GuoYue

doi:10.3969/j.issn.1001-5256.2018.06.030

Issue 6

Jun. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(6): 1282-1288

PDF( 1573 KB)

An analysis of risk factors for early complications after liver transplantation

DOI: 10.3969/j.issn.1001-5256.2018.06.030

First Department of Hepatopancreatobiliary Surgery, The First Hospital of Jilin University

Received Date: 2017-12-25
Published Date: 2018-06-20

Abstract

Abstract

Objective To investigate the risk factors for early complications after liver transplantation and to improve the prognosis. Methods The clinical data of 147 patients who underwent orthotopic liver transplantation in the Hepatic Transplantation Center of The First Hospital of Jilin University from September 2011 to April 2017 were retrospectively analyzed. According to the presence or absence of early complications after surgery, these patients were divided into non-complication group (n = 11) and complication group (n = 136) . The possible factors associated with early complications after surgery were collected, including donor factors (age and whether the blood type of the donor matches that of the recipient) , recipient factors (sex, age, primary disease, Model for End-Stage Liver Disease [MELD]score, aspartate aminotransferase [AST], alanine aminotransferase[ALT], albumin [Alb], platelet [PLT], hemoglobin [Hb], fibrinogen, total bilirubin, creatinine, PLT/Alb ratio [PAR], and neutrophil/lymphocyte ratio [NLR]) , intraoperative factors (cold ischemia time, warm ischemia time, intraoperative blood loss, and duration of anhepatic phase) , and postoperative factors (AST and ALT immediately and 12, 24, 48, and 72 hours after operation) . The clinical data were analyzed to investigate the association between these factors and early complications.The t test was used for comparison of normally distributed continuous data; the Mann-Whitney U test was used for comparison of non-normally distributed continuous data. The chi-square test was used for comparison of categorical data. Backward logistic regression was used for multivariate analysis. Results MELD score (t =-3. 86, P = 0. 002) , Alb (t = 2. 19, P = 0. 049) , PLT (Z = 467. 00, P = 0. 039) , PAR (Z = 500. 00, P = 0. 068) , fibrinogen (t = 1. 80, P = 0. 096) , TBil (Z =-1. 98, P = 0. 047) , preoperative AST (Z = 417. 00, P =0. 015) , and preoperative ALT (Z = 501. 50, P = 0. 070) were associated with postoperative complications. PAR and preoperative AST were independent risk factors for early complications (odds ratio [OR]= 3. 84, 95% confidence interval [CI]: 1. 03-14. 34, P < 0. 05; OR =0. 25, 95% CI: 0. 07-0. 94, P < 0. 05) . The 147 patients were divided into high-PAR group (PAR ≥3 × 109/g; n = 55) and low-PAR group (PAR < 3 × 109/g; n = 92) ; PAR was associated with postoperative vascular and biliary complications (χ2= 2. 87, P = 0. 090;χ2= 3. 54, P = 0. 060) . The 147 patients were divided into normal preoperative AST group (AST < 40 U/L; n = 93) and abnormal preoperative AST group (AST ≥40 U/L; n = 54) ; preoperative AST level was associated with postoperative pleural effusion (χ2= 3. 03, P =0. 082) . Conclusion Fibrinogen, PLT, Alb, TBil, PAR, MELD score, and preoperative AST and ALT are associated with the development of early complications after liver transplantation, and PAR and preoperative AST are independent risk factors for early complications.To improve the prognosis and postoperative survival, these factors, particularly PAR, should be fully assessed for the liver transplantation recipient before operation, and specific interventions should be provided accordingly.
- liver transplantation,
- postoperative complications,
- risk factors

FullText(HTML)

References(31)

References

[1]SHI YH, TIAN MX, FAN J.Recommendations for EASL clinical practice guidelines:liver transplantation (2015) [J].J Clin Hepatol, 2016, 31 (3) :429-431. (in Chinese) 史颖弘, 田孟鑫, 樊嘉.《欧洲肝病学会肝移植临床实践指南 (2015年) 》推荐意见[J].临床肝胆病杂志, 2016, 31 (3) :429-431.

[2]AZEVEDO LD, STUCCHI RS, ATAíDE EC.Assessment of causes of early death after twenty years of liver transplantation.[J].Transplant Proc, 2013, 45 (3) :1116-1118.

[3]DAI CL, YIN YE, LI H, et al.Significance of various detection methods in diagnosis of cytomegalovirus infection[J].Chin J Lab Diag, 2010, 14 (12) :2058-2059. (in Chinese) 戴春来, 尹艳娥, 李恒, 等.各种检测方法在巨细胞病毒感染诊断中的意义[J].中国实验诊断学, 2010, 14 (12) :2058-2059.

[4]CHEN XB, XU MQ.Primary graft dysfunction after liver transplantation[J].Hepatobiliary Pancreat Dis Int, 2014, 13 (2) :125-137.

[5]European Association for the Study of the Liver.EASL clinical practice guidelines:Liver transplantation[J].J Hepatol, 2016, 64 (2) :433-485.

[6]KOCHHAR G, PARUNGAO JM, HANOUNEH IA, et al.Biliary complications following liver transplantation[J].World J Gastroenterol, 2013, 19 (19) :2841-2846.

[7] WANG JY, LIAO EY, HUANG CX, et al.Internal medicine[M].Beijing:People's Medical Publishing House, 2013:662. (in Chinese) 王吉耀, 廖二元, 黄从新, 等.内科学[M].北京:人民卫生出版社, 2013:662.

[8]ZHOU L, PAN LC, SHI XJ, et al.Research advances in multicenter study on the role of the Model for End-Stage Liver Disease evaluation system in the selection of liver transplantation recipients[J].Organ Transplant, 2017, 8 (2) :174-178. (in Chinese) 周林, 潘立超, 史宪杰, 等.MELD评价体系对肝移植受者选择的多中心临床研究进展[J].器官移植, 2017, 8 (2) :174-178.

[9]SABATE A, DALMAU A.Fibrinogen:a clinical update on liver transplantation[J].Transplant Proc, 2015, 47 (10) :2925-2928.

[10]PORTE RJ, BLAUW E, KNOT EA, et al.Role of the donor liver in the origin of platelet disorders and hyperfibrinolysis in liver transplantation[J].J Hepatol, 1994, 21 (4) :592-600.

[11]JALAN R, SCHNURR K, MOOKERJEE RP, et al.Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality[J].Hepatology, 2009, 50 (2) :555-564.

[12]SHIRAI Y, SHIBA H, HARUKI K, et al.Preoperative platelet-to-albumin ratio predicts prognosis of patients with pancreatic ductal adenocarcinoma after pancreatic resection[J].Anticancer Res, 2017, 37 (2) :787-793.

[13]POROWSKI D, WIRKOWSKA A, HRYNIEWIECKA E, et al.Liver failure impairs the intrahepatic elimination of interleukin-6, tumor necrosis factor-alpha, hepatocyte growth factor, and transforming growth factor-beta[J].Biomed Res Int, 2015, 2015:934065.

[14]ALEXANDRAKIS MG, PASSAM FH, MOSCHANDREA IA, et al.Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis[J].Am J Clin Oncol, 2003, 26 (2) :135-140.

[15]GASTACA M.Biliary complications after orthotopic liver transplantation:A review of incidence and risk factors[J].Transplant Proc, 2012, 44 (6) :1545-1549.

[16]FREEMAN RB Jr, WIESNER RH, HARPER A, et al.The new liver allocation system:Moving toward evidence-based transplantation policy[J].Liver Transpl, 2002, 8 (9) :851-858.

[17] WANG XM, PENG CH, YAN JQ, et al.Relationship between Meld score and the perioperative complications and mortality after orthtopic liver transplantation[J].Chin J Organ Transplant, 2007, 28 (2) :105-107. (in Chinese) 王小明, 彭承宏, 严佶祺, 等.Meld评分与肝移植围手术期并发症及死亡率的相关性[J].中华器官移植杂志, 2007, 28 (2) :105-107.

[18]CHEN W, YI YX, ZHANG HB, et al.Evaluation effect of three scoring systems in the prediction of short-term outcomes following liver transplantation.[J].Chin J Hepatobiliary Surg, 2014, 20 (8) :557-561. (in Chinese) 陈威, 易永祥, 张海斌, 等.三种评分系统预测肝移植短期预后的效果评价[J].中华肝胆外科杂志, 2014, 20 (8) :557-561.

[19]WIEDERKEHR JC, IGREJA MR, NOGARA MS, et al.Analysis of survival after primary liver transplantation:Multivariate analysis of 155 cases in a single center[J].Transplant Proc, 2010, 42 (2) :511-512.

[20]SCHLEGEL A, LINECKER M, KRON P, et al.Risk assessment in high-and low-meld liver transplantation[J].Am J Transplant, 2017, 17 (4) :1050-1063.

[21]HALLDORSON JB, RAYHILL S, BAKTHAVATSALAM R, et al.Serum alkaline phosphatase and bilirubin are early surrogate markers for ischemic cholangiopathy and graft failure in liver transplantation from donation after circulatory death[J].Transplant Proc, 2015, 47 (2) :465-468.

[22]PLEVAK DJ, SOUTHORN PA, NARR BJ, et al.Intensive-care unit experience in the Mayo liver transplantation program:The first100 cases[J].Mayo Clinic Proceedings, 1989, 64 (4) :433-445.

[23]SHAHEEN AA, MYERS RP.Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C related fibrosis a systematic review[J].Hepatology, 2007, 46 (3) :912.

[24]EI SERAFY MA, KASSEM AM, OMAR H, et al.APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis:Systematic review and meta-analysis[J].Arab J Gastroenterol, 2017, 18 (2) :51-57.

[25]JAIN A, REYES J, KASHYAP R, et al.Long-term survival after liver transplantation in 4, 000 consecutive patients at a single center[J].Ann Surg, 2000, 232 (4) :490-500.

[26]DUFOUR DR, LOTT JA, NOLTE FS, et al.Diagnosis and monitoring of hepatic injury.II.Recommendations for use of laboratory tests in screening, diagnosis, and monitoring[J].Clin Chem, 2000, 46 (12) :2050-2068.

[27]BAHDE R, SPIEGEL HU.Hepatic ischaemia-reperfusion injury from bench to bedside[J].Br J Surg, 2010, 97 (10) :1461-1475.

[28]ARDITE E, RAMOS C, RIMOLA A, et al.Hepatocellular oxidative stress and initial graft injury in human liver transplantation[J].J Hepatol, 1999, 31 (5) :921-927.

[29]GIANNINI EG, TESTA R, SAVARINO V.Liver enzyme alteration:A guide for clinicians[J].CMAJ, 2005, 172 (3) :367-379.

[30]SEETO RK, FENN B, ROCKEY DC.Ischemic hepatitis:Clinical presentation and pathogenesis[J].Am J Med, 2000, 109 (2) :109-113.

[31]DETRY O, DEROOVER A, MEURISSE N, et al.Donor age as a risk factor in donation after circulatory death liver transplantation in a controlled withdrawal protocol progrankme[J].Br J Surg, 2014, 101 (7) :784-792.

Relative Articles

[1]	Yanhong BAO, Qiang WANG, Wenlong ZHANG, Na GE, Nan LI, Jun SU, Kexin LI. Ursolic acid in Hippophae rhamnoides L. inhibits hepatocyte apoptosis in rats with alcoholic liver disease by regulating mitochondria-cytochrome c[J]. Journal of Clinical Hepatology, 2023, 39(7): 1617-1626. doi: 10.3969/j.issn.1001-5256.2023.07.016
[2]	Ruibin WANG, Yuzheng LU, Jinglin ZHU, Wei WANG, Guang JIA. Inhibitory effect of lidocaine on Kupffer cell inflammatory response and its effect on liver abscess formation in diabetic mice[J]. Journal of Clinical Hepatology, 2022, 38(6): 1341-1346. doi: 10.3969/j.issn.1001-5256.2022.06.023
[3]	Jianan ZHAO, Jinghua PENG, Ping LIU, Yiyang HU. Effect of Cordyceps polysaccharides on hepatocyte apoptosis induced by tumor necrosis factor-α[J]. Journal of Clinical Hepatology, 2021, 37(6): 1368-1372. doi: 10.3969/j.issn.1001-5256.2021.06.029
[4]	Bi YanZhen, Zhang QiuSheng, Fan Zeng, Yang YongHong, Zhang XiaoBei, Wang QuanQuan, Wang QuanYi, Wang YiBo, Duan ZhongPing, Chen Yu, Shu ZhenFeng, Si ChuanPing, Hong Feng. Effect of human liver-derived stem cells in prevention and treatment of alcoholic fatty liver disease in mice[J]. Journal of Clinical Hepatology, 2019, 35(3): 592-595. doi: 10.3969/j.issn.1001-5256.2019.03.027
[5]	Gong Jing, Jie XinKe. Effect of endoplasmic reticulum stress and autophagy on hepatocyte apoptosis[J]. Journal of Clinical Hepatology, 2019, 35(12): 2828-2832. doi: 10.3969/j.issn.1001-5256.2019.12.041
[6]	Pan Jing, Pan WenTing, Wu LiHui. Expression and significance of Th22 cells and its functional factor interleukin-22 in mice with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1745-1749. doi: 10.3969/j.issn.1001-5256.2018.08.030
[7]	Gao Si, Zhao XiangXuan, Lu ZaiMing. Role of cell apoptosis regulated by P53 in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(7): 1373-1376. doi: 10.3969/j.issn.1001-5256.2017.07.038
[8]	Zhang ChaoYa, Zhao XiangXuan, Lu ZaiMing, Guo QiYong. Research advances in sorafenib- induced apoptotic signaling pathways in liver cancer cells[J]. Journal of Clinical Hepatology, 2016, 32(4): 816-820. doi: 10.3969/j.issn.1001-5256.2016.04.048
[9]	Pan LiuLan, Jia ShengNan, Ma JingTing, Tai JingHua, Jin ZhenJing. Effect of decoy receptor 3 gene on hepatocyte apoptosis[J]. Journal of Clinical Hepatology, 2016, 32(7): 1330-1333. doi: 10.3969/j.issn.1001-5256.2016.07.023
[10]	Zhang Xu, Wang Yu, Ma Juan, Wang ZhenZhen, Yuan Juan, Ma Yan, Liu Xin. Role of endoplasmic reticulum stress-mediated apoptosis in liver fibrosis[J]. Journal of Clinical Hepatology, 2015, 31(9): 1537-1539. doi: 10.3969/j.issn.1001-5256.2015.09.044
[11]	Peng Yuan, Tao YanYan, Huang Kai, Zhao Qiang, Liu ChengHai. Regulatory effect of poly I∶C on intrahepatic natural killer cells in mouse model of liver injury induced by carbon tetrachloride[J]. Journal of Clinical Hepatology, 2015, 31(12): 2077-2083. doi: 10.3969/j.issn.1001-5256.2015.12.022
[12]	Pan YuanWei, Ping Jian, Xu LieMing. Research advances in main signaling pathways for inducing apoptosis of activated hepatic stellate cells[J]. Journal of Clinical Hepatology, 2014, 30(2): 182-185. doi: 10.3969/j.issn.1001-5256.2014.02.021
[13]	Wang XiXun, Jiang LiXin, Wang JingLin, Liang Jing, Zhai HuiYuan, Xia XianMing. Experimental study on hepatocyte apoptosis induced by acute biliary tract infection[J]. Journal of Clinical Hepatology, 2014, 30(11): 1164-1168. doi: 10.3969/j.issn.1001-5256.2014.11.018
[14]	Weng ShanGeng, Xu ChangGuo, Sun Ying, Shi Zheng, Lin LiJuan. Study on the apoptosis of rat hepatic stellate cells induced by kapamycin[J]. Journal of Clinical Hepatology, 2012, 28(3): 219-222.
[15]	Qiao ChunPing, Chen YueXiang. Advances in study of the relationship between apoptosis and alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 386-390.
[16]	Zhang LiLi, Guo XiaoHong, Liu LiXin, Zhang QianQian. IGFBPrP1 siRNA induced apoptosis in rat hepatic stellate cells and its mechanism[J]. Journal of Clinical Hepatology, 2011, 27(9): 965-969+979.
[17]	Zhang Biao, Sui Tao, Yu XiuYing, Cao YongXian, Yao Yuan, He Hong. Significance of detecting apoptosis of PBMC and cytokine of supernatant induced by PHA in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2004, 20(3): 138-140.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	冯婧，高洪燕，黄山. 生化指标及自身抗体对原发性胆汁性肝硬化的诊断价值. 分子诊断与治疗杂志. 2021(07): 1039-1042 .
2.	刘蓉，陈清，熊美娥. 肝硬化门静脉高压患者的超声特点. 中国当代医药. 2019(22): 141-143 .
3.	董征. 原发性胆汁性肝硬化与病毒性肝炎肝硬化超声诊断的对比研究. 当代医学. 2019(29): 105-107 .
4.	杨璐萍，朱宗国，张然. 原发性胆汁性肝硬化患者免疫功能及肝功能损伤情况研究. 国际检验医学杂志. 2017(18): 2543-2545 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1776) PDF downloads(520)

An analysis of risk factors for early complications after liver transplantation

DOI: 10.3969/j.issn.1001-5256.2018.06.030